Early ctDNA Testing Provides Another Tool for Predicting Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma

Ryan J. Sullivan, MD, discusses previous research on tebentafusp in uveal melanoma that led to the inception of the IMCgp100-202 trial and clinical implications for data confirming the predictive value of circulating tumor DNA levels.

Related Keywords

Boston ,Massachusetts ,United States ,Ryanj Sullivan , ,Pfizer ,Novartis ,Harvard Medical School ,Bristol Myers Squibb ,Melanoma Program At Massachusetts ,Melanoma Program ,Massachusetts General Cancer ,Circulating Tumor Dna Testing ,Patients With Metastatic Uveal Melanoma Receiving Tebentafusp ,D ,Imcgp100 102 Trial ,Nct02570308 ,Imcgp100 202 Trial ,Nct03070392 ,